Christian Schumacher (RSS) (95)
Florian Winkler (RSS) (7)
Site Admin (RSS) (2)
guestpost (RSS) (2)
Andrew Armstrong (RSS) (1)
Megan Nichols (RSS) (1)
Indian government forces Bayer to accept generic Nexavar competition – FiercePharma
India has invoked its compulsory licensing rules for the first time, allowing the domestic drugmaker Natco Pharma to make and sell a version of Bayer’s cancer drug Nexavar–despite the fact that Nexavar is still on patent.
We think this is quite a significant development. What does it mean for ROI of big pharma companies R&D ? What does it mean for IP integrity for doing business in India ?
Indian government forces Bayer to accept generic Nexavar competition – FiercePharma.
Related Posts
24/04/2013 Big pharma´s patent wars in India
18/06/2013 US Supreme Court stops patenting of human genes
22/03/2012 Mr. Rossi´s e-cat patent and black box approach
18/03/2012 Rossi expects 5-year wait for US Patent on cold fusion
28/02/2012 Why ColdFusion/LENR has not been seized upon by private industry
Christian Schumacher
Dr. Christian Schumacher is the founder and managing director of StepChange Innovations GmbH, a technology development and consulting firm based in Germany. He has more than 20 years of experience in the chemical industry with global players such as Hoechst AG and DyStar Textilfarben GmbH as head of R&D, senior regional business manager Asia Pacific, head of e-commerce, head of marketing services, new product development manager and R&D chemist.
Follow Me: